Poster Abstracts • OFID 2018:5 (Suppl 1) • S147 more than one Candida spp. isolated were excluded. Patient data were collected using electronic medical records and microbiology laboratory reports.
Published clinical information on this organism consists primarily of case reports and small case series; thus, data from a single institution will allow us to examine risk factors for acquiring C. auris candidemia in comparison to other Candida species.
Methods. Aga Khan University Hospital Nairobi is a 280-bed referral center with 50 critical care beds. Candida species account for 34% of hospital acquired bloodstream infections (Maina et al., 2016) . Blood cultures were monitored continuously using the Bactec and the VitekII was used for identification and susceptibility. The VitekII identified C. auris as Candida haemulonii, but species determinations were done for 21 of the isolates and all were identified as C. auris using published methods (Pfaller et al., 2012) .
Results. From September 2010 to December 2016, 201 patients had 228 episodes of candidemia. Further analyses were performed only for first episodes. C. auris accounted for 38% of candidemia cases and 25% for C. albicans. A case-control analysis was done to compare patients with C. auris vs. Candida albicans fungemia. C. auris patients were more likely to be from critical care beds (78% vs. 52%; P = 0.003) and had been hospitalized longer (mean 33 days vs. 13 days; P < 0.001) prior to the positive blood culture. There was a trend toward more pre-existing renal failure (39% vs. 24%; P = 0.09) in C. auris patients and during the two weeks prior to candidemia, they were more likely to have central lines (84% vs. 54%; P ≤ 0.001). C. auris patients received a mean of 3.35 antibiotic classes vs. 2.6 for C. albicans (P = 0.02). 75% of C. auris patients received carbapenems vs. 54% for C. albicans (P = 0.02). Eighteen percent of C. auris patients had ≥14 days of candidemia, despite frequent lack of followup blood cultures. Prolonged candidemia was not associated with development of in vitro resistance. The crude mortality was 29%, compared with 36% for C. albicans and 39% for other Candida spp. (NS).
Conclusion. These findings suggest an opportunistic pathogen that may be less virulent, but difficult to eradicate and that control efforts should focus on antimicrobial usage. Background. The emerging multidrug-resistant yeast Candida auris can cause invasive infections associated with high mortality. To date, a majority of C. auris infections have been reported among adults. This report describes cases of pediatric C. auris bloodstream infections (BSI) that occurred during January 2015-September 2016 at two hospitals in Colombia.
Methods. After the Colombian National Institute of Health released a clinical alert about C. auris in September 2016, we conducted a retrospective review of microbiology records for possible C. auris cases in two acute care hospitals in Barranquilla and Cartagena. BSIs occurring in patients <18 years confirmed as C. auris were included in this analysis. Patient information was collected from medical records.
Results. We identified 34 children with C. auris BSI. Cases appeared to cluster in time within each hospital (Figure 1 ). Twenty-two (65%) patients were male, 21% were <28 days old, 47% were 29-365 days old, and 32% were >1 year. Underlying conditions included preterm birth (26%), altered nutritional status (59%), cancer (12%), solid-organ transplant (3%), and renal disease (3%). Eighty-two percent had a central venous catheter (CVC), 82% on respiratory support, 56% received total parenteral nutrition (TPN), 15% had a surgical procedure, and 9% received hemodialysis. All patient received antibiotics in the 14 days before C. auris BSI, and 97% received antifungal treatment for BSI. Median inpatient stay before onset of C. auris BSI was 22 days (interquartile range: 17-30 days), and in-hospital mortality was 41%.
Conclusion. Similar to other Candida BSI, C. auris affects children with a variety of medical conditions including prematurity, malignancy, and those with CVCs, and receiving TPN. Mortality was high, with nearly half of patients dying before discharge. However, unlike most other Candida species, C. auris can be transmitted in healthcare settings, as suggested by the close clustering of cases in time at each of the hospitals. Pediatric wards should be vigilant for C. auris outbreaks and take necessary infection control measures to stop the spread of the organism. 
